Critical Outcome Technologies Inc. achieves milestones moving COTI-2 closer to IND filing

London, Ontario (September 11, 2012): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that it has finalized an oral formulation for COTI-2 in moving forward to the final preclinical studies supporting the investigational new drug (IND) submission enabling a Phase 1 clinical trial. This oral formulation is designed to optimize the absorption of an orally administered…